|
1
|
Ashtekar DR, Costa-Periera R, Shrinivasan
T, Iyyer R, Vishvanathan N and Rittel W: Oxazolidinones, a new
class of synthetic antituberculosis agent. In vitro and in vivo
activities of DuP-721 against Mycobacterium tuberculosis. Diagn
Microbiol Infect Dis. 14:465–471. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jones RN, Johnson DM and Erwin ME: In
vitro antimicrobial activities and spectra of U-100592 and
U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents
Chemother. 40:720–726. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaatz GW and Seo SM: In vitro activities
of oxazolidinone compounds U100592 and U100766 against
Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob
Agents Chemother. 40:799–801. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meagher AK, Forrest A, Rayner CR,
Birmingham MC and Schentag JJ: Population pharmacokinetics of
linezolid in patients treated in a compassionate-use program.
Antimicrob Agents Chemother. 47:548–553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Condos R, Hadgiangelis N, Leibert E,
Jacquette G, Harkin T and Rom WN: Case series report of a
linezolid-containing regimen for extensively drug-resistant
tuberculosis. Chest. 134:187–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fortun J, Martin-Davila P, Navas E,
Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E
and Moreno S: Linezolid for the treatment of multidrug-resistant
tuberculosis. J Antimicrob Chemother. 56:180–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park IN, Hong SB, Oh YM, Kim MN, Lim CM,
Lee SD, Koh Y, Kim WS, Kim DS, Kim WD and Shim TS: Efficacy and
tolerability of daily-half dose linezolid in patients with
intractable multidrug-resistant tuberculosis. J Antimicrob
Chemother. 58:701–704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cynamon MH, Klemens SP, Sharpe CA and
Chase S: Activities of several novel oxazolidinones against
mycobacterium tuberculosis in a murine model. Antimicrob Agents
Chemother. 43:1189–1191. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Molicotti P, Ortu S, Bua A, Cannas S,
Sechi LA and Zanetti S: In vitro efficacy of Linezolid on clinical
strains of Mycobacterium tuberculosis and other mycobacteria. New
Microbiol. 29:275–280. 2006.PubMed/NCBI
|
|
10
|
Sood R, Bhadauriya T, Rao M, Gautam R,
Malhotra S, Barman TK, Upadhyay DJ and Rattan A: Antimycobacterial
activities of oxazolidinones: A review. Infect Disord Drug Targets.
6:343–354. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Keel RA, Schaeftlein A, Kloft C, Pope JS,
Knauft RF, Muhlebach M, Nicolau DP and Kuti JL: Pharmacokinetics of
intravenous and oral linezolid in adults with cystic fibrosis.
Antimicrob Agents Chemother. 55:3393–3398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sazdanovic P, Jankovic SM, Kostic M,
Dimitrijevic A and Stefanovic S: Pharmacokinetics of linezolid in
critically ill patients. Expert Opin Drug Metab Toxicol.
12:595–600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buerger C, Plock N, Dehghanyar P,
Joukhadar C and Kloft C: Pharmacokinetics of unbound linezolid in
plasma and tissue interstitium of critically ill patients after
multiple dosing using microdialysis. Antimicrob Agents Chemother.
50:2455–2463. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calzada Y, Jordan I, Vila-Perez D, Cambra
FJ and Munoz-Almagro C: Pleuropneumonia and septic shock due to
multiresistant Streptococcus pneumoniae serotype 19A treated with
linezolid. An Pediatr (Barc). 81:e22–23. 2014.(In Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Bels D, Garcia-Filoso A, Jeanmaire M,
Preseau T, Miendje Deyi VY and Devriendt J: Successful treatment
with linezolid of septic shock secondary to methicillin-resistant
Staphylococcus aureus arthritis. J Antimicrob Chemother.
55:812–813. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rac H, Bojikian KD, Lucar J and Barber KE:
Successful treatment of necrotizing fasciitis and streptococcal
toxic shock syndrome with the addition of linezolid. Case Rep
Infect Dis. 2017:57207082017.PubMed/NCBI
|
|
17
|
Stevens DL, Wallace RJ, Hamilton SM and
Bryant AE: Successful treatment of staphylococcal toxic shock
syndrome with linezolid: A case report and in vitro evaluation of
the production of toxic shock syndrome toxin type 1 in the presence
of antibiotics. Clin Infect Dis. 42:729–730. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang DD, Lu JM, Li Q and Li ZP: Population
pharmacokinetics of tacrolimus in paediatric systemic lupus
erythematosus based on real-world study. J Clin Pharm Ther.
43:476–483. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vadcharavivad S, Praisuwan S,
Techawathanawanna N, Treyaprasert W and Avihingsanon Y: Population
pharmacokinetics of tacrolimus in Thai kidney transplant patients:
Comparison with similar data from other populations. J Clin Pharm
Ther. 41:310–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sahuquillo Arce JM, Colombo Gainza E, Gil
Brusola A, Ortiz Estevez R, Canton E and Gobernado M: In vitro
activity of linezolid in combination with doxycycline, fosfomycin,
levofloxacin, rifampicin and vancomycin against
methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter.
19:252–257. 2006.PubMed/NCBI
|
|
21
|
Sweeney MT and Zurenko GE: In vitro
activities of linezolid combined with other antimicrobial agents
against Staphylococci, Enterococci, Pneumococci, and selected
gram-negative organisms. Antimicrob Agents Chemother. 47:1902–1906.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Beitdaghar M, Ahmadrajabi R, Karmostaji A
and Saffari F: In vitro activity of linezolid alone and combined
with other antibiotics against clinical enterococcal isolates. Wien
Med Wochenschr. 169:215–221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Craig WA: Basic pharmacodynamics of
antibacterials with clinical applications to the use of
beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North
Am. 17:479–501. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roger C, Muller L, Wallis SC, Louart B,
Saissi G, Lipman J, Lefrant JY and Roberts JA: Population
pharmacokinetics of linezolid in critically ill patients on renal
replacement therapy: Comparison of equal doses in continuous
venovenous haemofiltration and continuous venovenous
haemodiafiltration. J Antimicrob Chemother. 71:464–470. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rayner CR, Forrest A, Meagher AK,
Birmingham MC and Schentag JJ: Clinical pharmacodynamics of
linezolid in seriously ill patients treated in a compassionate use
programme. Clin Pharmacokinet. 42:1411–1423. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang DD, Lu JM, Li YZ, Li Q and Li ZP:
Population pharmacokinetics of sirolimus in pediatric tuberous
sclerosis complex: From real world study. Int J Clin Exp Med.
11:12302–12309. 2018.
|
|
27
|
Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X,
Chen C and Li Z: Population pharmacokinetics of vancomycin and
AUC-guided dosing in Chinese neonates and young infants. Eur J Clin
Pharmacol. 74:921–930. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gong Y, Chen Y, Li Q and Li Z: Population
pharmacokinetic analysis of digoxin in Chinese neonates and
infants. J Pharmacol Sci. 125:142–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y,
Wu D, Zhu Y, Wang Y and Chen C: Population pharmacokinetics of
piperacillin/tazobactam in neonates and young infants. Eur J Clin
Pharmacol. 69:1223–1233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Andrews LM, Hesselink DA, van Gelder T,
Koch BC, Cornelissen EA, Bruggemann RJ, van Schaik RH, de Wildt SN,
Cransberg K and de Winter BC: A population pharmacokinetic model to
predict the individual starting dose of tacrolimus following
pediatric renal transplantation. Clin Pharmacokinet. 57:475–489.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu ZC, Zhou PJ, Wang XH, Francoise B, Xu
D, Zhang WX and Chen B: Population pharmacokinetics and Bayesian
estimation of mycophenolic acid concentrations in Chinese adult
renal transplant recipients. Acta Pharmacol Sin. 38:1566–1579.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen B, Shi HQ, Liu XX, Zhang WX, Lu JQ,
Xu BM and Chen H: Population pharmacokinetics and Bayesian
estimation of tacrolimus exposure in Chinese liver transplant
patients. J Clin Pharm Ther. 42:679–688. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chevillard L, Sabo N, Tod M, Labat L,
Chasport C, Chevaleyre C, Thibaut F, Barre J, Azuar J, Questel F,
et al: Population pharmacokinetics of oral baclofen at steady-state
in alcoholic-dependent adult patients. Fundam Clin Pharmacol.
32:239–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Plock N, Buerger C, Joukhadar C, Kljucar S
and Kloft C: Does linezolid inhibit its own metabolism? Population
pharmacokinetics as a tool to explain the observed nonlinearity in
both healthy volunteers and septic patients. Drug Metab Dispos.
35:1816–1823. 2007. View Article : Google Scholar : PubMed/NCBI
|
